ProTarget
A Danish Nationwide Clinical Trial on Targeted
Cancer Treatment Based on Genomic Profiling
Latest News
News from the ProTarget trial
Researchers from the Danish cancer centers participating in ProTarget have taken important steps toward harmonizing molecular diagnostics across Denmark. In a recently published study in Acta Oncologica, Dr. Christine Federspiel Secher and colleagues reported...
Read More
As the year 2025 comes to an end, we reflect on a series of achievements in ProTarget and conclude with a little surprise looking ahead. 2025 marked a highly significant year for the trial, with major scientific milestones, expanded treatment opportunities, an...
Read More
About us
The ProTarget study - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on Genomic Profiling
The ProTarget study is a Danish investigator-initiated phase 2 clinical trial that aims to facilitate patient access to commercially available molecularly targeted anti-cancer drugs based on tumor genomic profiling.
The trial aims to investigate the safety and efficacy of these treatments, when they are used outside the labeled indication to treat patients with relevant actionable targets. By doing this, we aim to identify new predictive biomarkers for targeted treatments outside the labeled indication and provide new data and essential insights in molecular pathways involved in e.g., resistance to targeted therapies.